Prof. José Baselga has passed on March 21st
Dr.Baselga was an amazing oncologist& researcher who paved the way for many molecular targeted therapies
in2017 was awarded the @myESMO Lifetime Achievement Award
Huge loss for the Oncology Community
Our thoughts are with his family
OncoAlert
122.1K posts
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
- Colleagues In Response to the invasion of Ukraine🇺🇦, the @OncoAlert 🚨network will be pulling out of ALL collaborations & congresses in Russia We're non political, but we must take a stand against the injustices & aggression being directed towards Ukraine‼️ Best, The Network🌐
- Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG) #CancerHasNoAge 🚨 buff.ly/lg73Tsp Immune checkpoint inhibitors (ICIs) have significantly improved
- The OncoAlert Network has ZERO tolerance for sexual harassment or abuse of any type & stand by our values. These kinds of actions are inexcusable and we condemn them wholeheartedly!! Sincerely, The OncoAlert Network
- Dear friends An Amazing way to start #ESMO21 Our biggest heartfelt CONGRATULATIONS to the Heart & Soul of your @OncoAlert network @DrChoueiri who has just been named a GIANT of #Cancer care @GiantsofCC @GCCAwards We are SO PROUD & congratulate him on this well deserved award!
- New guidelines alert🚨 The 2024 EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines for #ProstateCancer offer personalized recommendations for screening, diagnosis, and treatment based on the latest data. Emphasizing risk-adapted approaches and advanced imaging, these guidelines reflect
- Dear Colleagues, The @OncoAlert 🚨Newsletter for the entire #ASCO23 congress is out (DAYS 1-5)‼️ To receive it simply register at OncoAlert360.com ADAURA🫁 #LungCancer #LCSM CONTACT 03 #KidneyCancer PROSPECT🔨 #RectalCancer MONARCH E🦋 #BreastCancer NATALEE KEYNOTE-671🗝️
00:00 - Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials out on @JCO_ASCO Study investigates the impact of immunosuppressive treatment💊 on survival in patients with various tumor types receiving anti–PD-1 +
- Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial buff.ly/3C69NRa The phase III EMERALD trial
- The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 ⭐ Abs 8506: HERTHENA-LUNG02: PATRITUMAB DERUXTECAN IN RESISTANT EGFR-MUTATED ADVANCED NON-SMALL
- WOW, What a way to Spend our BIRTHDAY THANK YOU DEAR COLLEAGUES Our Solidarity and Power of community never ceases to AMAZE ME!!! WE ARE ALL @OncoAlert 🚨 and WE ARE BACK‼️ My Sincere Gratitude, @weoncologists 🤠
00:00 - SPECIAL⭐️ @OncoAlert 🚨NEWSLETTER #WCLC23 World Conference🫁 #LungCancer 🇸🇬 TO GET IT REGISTER AT: OncoAlert360.com ✅FLAURA2⃣ ✅MARS2⃣🪐 ✅TMN Staging🔬 ✅DESTINY LUNG0⃣2⃣ ✅Herthena🫁 ✅TRIDENT🔱 ✅EVOKE ✅ISABR☢️ ✅RIOT🪖 and more A great way to catch up on all the
00:00 - The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB
- Our warmest congratulations to the heart & Soul of our @OncoAlert 🚨Network on being elected to the ESMO nomination Committee‼️ All for one ⚔️ One for All












